News

Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights March 30, 2026 PDF Version Accelerated Phase 3 CoMpass Enrollment Supports Mid-2026 Enrollment Completion and 2H 2027 Topline Data Guidance Phase 1b/2 NMIBC Trial on Track: Initial 3-Month Clinical Data Expected Mid-2026 12-month Stability Completed with New Formulation with Potential Across…

Read more

Aura Biosciences to Participate in Upcoming Investor Conferences

February 25, 2026PDF Version BOSTON, Feb. 25, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: TD Cowen 46th Annual Health Care Conference…

Read more

Aura Biosciences Reports Third Quarter 2025 Financial Results and Business Highlights

November 13, 2025PDF Version Aura Provides Phase 3 CoMpass Trial Completion Guidance: 2026 Enrollment Completion and Q4 2027 Topline Data Readout for the 15-Month Primary Endpoint Immune Profiling Data Reveal Bel-sar’s Potential to Convert ‘Cold’ to ‘Hot’ Tumors, Supporting a Frontline Therapy Across the Bladder Cancer Spectrum; Phase 1b/2 Trial is on Track for Data Mid-2026…

Read more

Aura Biosciences to Participate in the 8th Annual Evercore Healthcare Conference

November 24, 2025PDF Version BOSTON, Nov. 24, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025, at 10:50 a.m. ET. The live webcast…

Read more